COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08KQK
|
|||
| Drug Name |
PMID31244113-compound-2c
|
|||
| Synonyms |
PMID31244113-C-2c
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Middle East Respiratory Syndrome (MERS) | Preclinical | [1] | Severe acute respiratory syndrome (SARS) | Preclinical | [1] |
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | MERS-CoV RNA-directed RNA polymerase (RdRp) | Target Info | Inhibitor | [1] |
| Compounds 2c exhibits a promising inhibitory activity against MERS-Cov RdRp with EC50 of 0.5 microM. | ||||
| SARS-CoV RNA-directed RNA polymerase (RdRp) | Target Info | Inhibitor | [1] | |
| 6',6'-Difluoroaristeromycin (2c) shows the strongest antiviral effect for SARS-CoV RdRp, with a 2.5 log reduction in infectious progeny titer in viral load reduction assay. | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | Design, Synthesis, and Anti-RNA Virus Activity of 6'-Fluorinated-Aristeromycin Analogues. J Med Chem. 2019 Jul 11;62(13):6346-6362. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.